Related references
Note: Only part of the references are listed.The role of Denosumab in joint preservation for patients with giant cell tumour of bone
D. L. Perrin et al.
BONE & JOINT JOURNAL (2021)
Propensity score matching with R: conventional methods and new features
Qin-Yu Zhao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis
Xi Chen et al.
BMC MUSCULOSKELETAL DISORDERS (2020)
Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy
C. Y. Lim et al.
BONE & JOINT JOURNAL (2020)
Denosumab for giant cell tumour of bone: success and limitations
John H. Healey
LANCET ONCOLOGY (2019)
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
Sant Chawla et al.
LANCET ONCOLOGY (2019)
Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Guido Scoccianti et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2018)
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial
Piotr Rutkowski et al.
EJSO (2018)
Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage
Costantino Errani et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2018)
Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series
Ilaria Girolami et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone
Frank Traub et al.
EUROPEAN JOURNAL OF CANCER (2016)
Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone
Piotr Rutkowski et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab
Tobias A. Mattei et al.
SPINE JOURNAL (2014)
Bone Cancer Clinical Practice Guidelines in Oncology
J. Sybil Biermann et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
Sant Chawla et al.
LANCET ONCOLOGY (2013)
Giant Cell Tumor of Bone Risk Factors for Recurrence
Frank M. Klenke et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2011)
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
David Thomas et al.
LANCET ONCOLOGY (2010)
Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy
F. Malek et al.
INTERNATIONAL ORTHOPAEDICS (2006)
Impending fractures in giant cell tumours of the distal femur: incidence and outcome
LM Jeys et al.
INTERNATIONAL ORTHOPAEDICS (2006)
Results of giant cell tumor of bone treated with intralesional excision
P Saiz et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2004)
Treatment of stages 2 and 3 giant-cell tumor
K Labs et al.
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY (2001)
Share Paper
